Developer docs
API playgroundTry for free, no card

Search company profiles

Pfizer Australia

Full company profile

uuid002a2hu

Namestring
Pfizer Australia
Legal namestring
Pfizer Australia Pty Limited
Websiteurl
pfizer.com.au
Company typeenum
Private
Founded yearint
1960
Descriptiontext

Pfizer Australia is a wholly-owned subsidiary of Pfizer Inc. (NYSE: PFE), operating as a biopharmaceutical company across Australia, New Zealand, and Papua New Guinea. Founded circa 1960, the entity has operated locally for over 65 years as part of Pfizer's 175-year global biopharmaceutical heritage. Its core offering is a diversified prescription medicines, vaccines, and therapeutics portfolio spanning six therapeutic areas: Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS), meaning pricing is government-regulated through reimbursement decisions.

The company generates revenue through a multi-channel go-to-market model. Field sales representatives and customer engagement teams engage healthcare professionals directly (supported by the 1800 PFIZER HCP line and 1800 675 229 medical information line). PfizerDirect provides pharmacies with real-time stock visibility and Key Account support via pfizerpharmacyhub.com.au. Hospital sales cover therapeutic areas including anti-infectives. A biopharma wholesaler network handles broader distribution, with primary depot partners trading at minimum $10M annually. Medicines access programs (Cost-Share Agreements, Compassionate Access Programs, Product Familiarisation Programs) supplement standard distribution for eligible patients.

Pfizer Australia's competitive position rests on the Pfizer global brand, the depth of Pfizer Inc.'s R&D pipeline feeding the local portfolio, PBS regulatory listing barriers, and an entrenched commercial ecosystem that includes the PfizerPro HCP portal, dedicated medical information services, clinical trial operations, and policy advocacy (Breakthrough Nation report, Stronger PBS campaign). The company maintains Medicines Australia Code of Conduct transparency reporting and engages in CSR through The Smith Family partnership (since 2016, $550,000+ invested). Leadership is anchored by Managing Director Anne Harris. The subsidiary operates with a lean 51-100 employee headcount consistent with a commercial and corporate team that draws on parent-company R&D and global manufacturing infrastructure.

Short descriptiontext

Pfizer Australia is the Sydney-based ANZ/PNG biopharmaceutical subsidiary of Pfizer Inc., selling PBS-listed prescription medicines, vaccines, and therapeutics across six therapeutic areas to healthcare professionals, pharmacies, and hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription medicines, biopharmaceutical products, vaccines therapeutics, clinical trials research, hospital pharmaceuticals
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Medicines and Vaccines
TypeOne Time License
Description

Pfizer Australia generates revenue through the sale of prescription medicines, vaccines, and therapeutics distributed via pharmacies, hospitals, and healthcare providers. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS) which affects pricing and reimbursement.

pfizer.com.au
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1PBS-listed products subject to government-regulated pricing
ModelOtherBilling cadenceOther
Notes

Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS) with government-subsidized pricing for eligible patients. Pricing varies by product and is not publicly disclosed on the website.

pfizer.com.au
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pfizer Australia manufactures and sells biopharmaceutical products including prescription medicines, vaccines, and therapeutics across therapeutic areas such as Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are distributed via pharmacies, hospitals, wholesalers, and healthcare providers, with pricing governed by Australia's Pharmaceutical Benefits Scheme (PBS). The company also runs clinical trials, medicines access programs, and healthcare-professional support services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pfizer Australia operates as a biopharmaceutical company offering a portfolio of medicines, vaccines, and therapeutics across multiple therapeutic areas including Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. The company provides Consumer Medicine Information and Product Information resources for consumers and healthcare professionals, along with patient support programs, access programs, and health education resources.

Product and service3 records
1PfizerDirect Pharmacy Service
CategoryPharmacy distribution and logistics service
Description

Direct B2B service for pharmacy customers providing real-time stock status and connection with Pfizer's Key Account team via pfizerpharmacyhub.com.au, supporting product ordering, logistics, and supply chain visibility for pharmacies and wholesalers.

2Medicines Access Programs
CategoryPatient and healthcare professional access programs
Description

A suite of programs including Cost-Share Agreements, Compassionate Access Programs, and Product Familiarisation Programs designed to facilitate access to Pfizer medicines for eligible patients and support healthcare organisations managing treatment pathways.

3Clinical Trials
CategoryClinical research and medicine development
Description

Clinical trial programs conducted in Australia as part of Pfizer's global medicine development process, supporting research across its therapeutic areas.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOthersAnnounced on2016-01-01
Description

Since 2016, Pfizer has supported The Smith Family as its Charity of Choice in Australia. Over the course of the partnership, Pfizer has invested more than $550,000 to support education of young Australians in need. Pfizer currently sponsors 72 students on the Learning for Life program, including 35 students who identify as Aboriginal or Torres Strait Islander. Pfizer colleagues volunteer through student profile checking, career activities, and letter/card writing programs.

Strategic tierMinorTypeOthers
Description

McGrath Foundation is listed as one of Pfizer's charity impact report partners, indicating a charitable giving or support relationship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pfizer Australia is a member of Medicines Australia and committed to transparency reporting under the Medicines Australia Code of Conduct Edition 20. Reports publicly disclose transfers of value to healthcare professionals, sponsorship of third-party educational meetings, grants and donations to healthcare organisations, and support to patient organisations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian subsidiary of Bayer with portfolio overlap in specialty pharmaceuticals and women's health, plus similar PBS-driven, HCP-focused commercial model. Comparable multinational pharma subsidiary competing in the same Australian market.

2Roche Australia
TypeDirect peer
Description

Australian subsidiary of Roche, another major multinational biopharmaceutical company with a comparable broad therapeutic portfolio including oncology, immunology, and rare disease. Directly comparable as a peer multinational pharma subsidiary operating in the same PBS-regulated market.

3GSK Australia
TypeDirect peer
Description

Australian subsidiary of GSK with strong overlap in vaccines, specialty medicines, and hospital therapeutics. Competes directly with Pfizer across HCP engagement, PBS listings, and respiratory portfolios.

TypeDirect peer
Description

Australian subsidiary of Novartis with overlapping therapeutic areas including oncology, rare disease, and immunology. Operates under the same PBS reimbursement regime and engages HCPs and hospitals through similar field-sales models.

TypeDirect peer
Description

Australian arm of AstraZeneca with overlapping portfolios in oncology, vaccines, and respiratory. Operates the same field-sales, hospital, and PBS-driven commercial model in Australia.

TypeDirect peer
Description

Pharmaceutical arm of J&J in Australia, with overlapping portfolios in oncology, immunology, and rare disease. Competes for the same HCP relationships, hospital listings, and PBS reimbursement slots as Pfizer Australia.

7Sanofi Australia
TypeDirect peer
Description

Australian subsidiary of Sanofi with portfolio overlap in vaccines, rare disease, and specialty care. Operates the same PBS, HCP, and pharmacy distribution model targeting the same Australian prescriber base.

TypeDirect peer
Description

Australian subsidiary of Eli Lilly with growing focus on oncology, diabetes, and immunology. Operates a similar PBS, HCP, and hospital-focused commercial model targeting the same Australian prescriber base as Pfizer Australia.

9AbbVie Australia
TypeDirect peer
Description

Australian subsidiary of AbbVie with strong overlap in immunology, oncology, and neuroscience. Competes directly with Pfizer for HCP relationships, hospital listings, and PBS positions in Australia.

TypeDirect peer
Description

Australian subsidiary of Merck & Co. with a comparable portfolio in vaccines, oncology, and hospital specialty. Competes head-to-head with Pfizer for HCP attention, hospital listings, and PBS positions.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pfizer Australia

Biopharmaceuticalspfizer.com.au

Pfizer Australia is the Sydney-based ANZ/PNG biopharmaceutical subsidiary of Pfizer Inc., selling PBS-listed prescription medicines, vaccines, and therapeutics across six therapeutic areas to healthcare professionals, pharmacies, and hospitals.

What Pfizer Australia does

Pfizer Australia is a wholly-owned subsidiary of Pfizer Inc. (NYSE: PFE), operating as a biopharmaceutical company across Australia, New Zealand, and Papua New Guinea. Founded circa 1960, the entity has operated locally for over 65 years as part of Pfizer's 175-year global biopharmaceutical heritage. Its core offering is a diversified prescription medicines, vaccines, and therapeutics portfolio spanning six therapeutic areas: Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS), meaning pricing is government-regulated through reimbursement decisions.

The company generates revenue through a multi-channel go-to-market model. Field sales representatives and customer engagement teams engage healthcare professionals directly (supported by the 1800 PFIZER HCP line and 1800 675 229 medical information line). PfizerDirect provides pharmacies with real-time stock visibility and Key Account support via pfizerpharmacyhub.com.au. Hospital sales cover therapeutic areas including anti-infectives. A biopharma wholesaler network handles broader distribution, with primary depot partners trading at minimum $10M annually. Medicines access programs (Cost-Share Agreements, Compassionate Access Programs, Product Familiarisation Programs) supplement standard distribution for eligible patients.

Pfizer Australia's competitive position rests on the Pfizer global brand, the depth of Pfizer Inc.'s R&D pipeline feeding the local portfolio, PBS regulatory listing barriers, and an entrenched commercial ecosystem that includes the PfizerPro HCP portal, dedicated medical information services, clinical trial operations, and policy advocacy (Breakthrough Nation report, Stronger PBS campaign). The company maintains Medicines Australia Code of Conduct transparency reporting and engages in CSR through The Smith Family partnership (since 2016, $550,000+ invested). Leadership is anchored by Managing Director Anne Harris. The subsidiary operates with a lean 51-100 employee headcount consistent with a commercial and corporate team that draws on parent-company R&D and global manufacturing infrastructure.

Pfizer Australia firmographics

Firmographics
Name
Pfizer Australia
Legal name
Pfizer Australia Pty Limited
Website
https://pfizer.com.au
Company type
Private
Founded year
1960
Operating status
Operating
Headcount range
51–100 employees
Short description
Pfizer Australia is the Sydney-based ANZ/PNG biopharmaceutical subsidiary of Pfizer Inc., selling PBS-listed prescription medicines, vaccines, and therapeutics across six therapeutic areas to healthcare professionals, pharmacies, and hospitals.
Ownership category
akta.pro rank

Pfizer Australia industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription medicines
  • Biopharmaceutical products
  • Vaccines therapeutics
  • Clinical trials research
  • Hospital pharmaceuticals

Where Pfizer Australia is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Pfizer Australia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Prescription Medicines and Vaccines: Pfizer Australia generates revenue through the sale of prescription medicines, vaccines, and therapeutics distributed via pharmacies, hospitals, and healthcare providers. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS) which affects pricing and reimbursement.

Pricing tiers

ModelBillingPrice
OtherOtherPBS-listed products subject to government-regulated pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Pfizer Australia product offering

Product offering

Core offering

Pfizer Australia manufactures and sells biopharmaceutical products including prescription medicines, vaccines, and therapeutics across therapeutic areas such as Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are distributed via pharmacies, hospitals, wholesalers, and healthcare providers, with pricing governed by Australia's Pharmaceutical Benefits Scheme (PBS). The company also runs clinical trials, medicines access programs, and healthcare-professional support services.

Product overview

Pfizer Australia operates as a biopharmaceutical company offering a portfolio of medicines, vaccines, and therapeutics across multiple therapeutic areas including Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. The company provides Consumer Medicine Information and Product Information resources for consumers and healthcare professionals, along with patient support programs, access programs, and health education resources.

Differentiator

Problem solved

Functional benefit

Products and services

  • PfizerDirect Pharmacy Service Direct B2B service for pharmacy customers providing real-time stock status and connection with Pfizer's Key Account team via pfizerpharmacyhub.com.au, supporting product ordering, logistics, and supply chain visibility for pharmacies and wholesalers.
  • Medicines Access Programs A suite of programs including Cost-Share Agreements, Compassionate Access Programs, and Product Familiarisation Programs designed to facilitate access to Pfizer medicines for eligible patients and support healthcare organisations managing treatment pathways.
  • Clinical Trials Clinical trial programs conducted in Australia as part of Pfizer's global medicine development process, supporting research across its therapeutic areas.

Companies that use Pfizer Australia

Customer profile

Segments4 records

Ideal customer profiles3 records

Pfizer Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pfizer Australia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • The Smith FamilycoreOthers · 1 January 2016Since 2016, Pfizer has supported The Smith Family as its Charity of Choice in Australia. Over the course of the partnership, Pfizer has invested more than $550,000 to support education of young Australians in need. Pfizer currently sponsors 72 students on the Learning for Life program, including 35 students who identify as Aboriginal or Torres Strait Islander. Pfizer colleagues volunteer through student profile checking, career activities, and letter/card writing programs.
  • McGrath FoundationminorOthersMcGrath Foundation is listed as one of Pfizer's charity impact report partners, indicating a charitable giving or support relationship.
  • Medicines AustraliacoreStrategic or Co-development PartnerPfizer Australia is a member of Medicines Australia and committed to transparency reporting under the Medicines Australia Code of Conduct Edition 20. Reports publicly disclose transfers of value to healthcare professionals, sponsorship of third-party educational meetings, grants and donations to healthcare organisations, and support to patient organisations.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Pfizer Australia competitors and assessment

Company assessment

Direct peers

  • Bayer Australia: Australian subsidiary of Bayer with portfolio overlap in specialty pharmaceuticals and women's health, plus similar PBS-driven, HCP-focused commercial model. Comparable multinational pharma subsidiary competing in the same Australian market.
  • Roche Australia: Australian subsidiary of Roche, another major multinational biopharmaceutical company with a comparable broad therapeutic portfolio including oncology, immunology, and rare disease. Directly comparable as a peer multinational pharma subsidiary operating in the same PBS-regulated market.
  • GSK Australia: Australian subsidiary of GSK with strong overlap in vaccines, specialty medicines, and hospital therapeutics. Competes directly with Pfizer across HCP engagement, PBS listings, and respiratory portfolios.
  • Novartis Australia: Australian subsidiary of Novartis with overlapping therapeutic areas including oncology, rare disease, and immunology. Operates under the same PBS reimbursement regime and engages HCPs and hospitals through similar field-sales models.
  • AstraZeneca Australia: Australian arm of AstraZeneca with overlapping portfolios in oncology, vaccines, and respiratory. Operates the same field-sales, hospital, and PBS-driven commercial model in Australia.
  • Johnson & Johnson Innovative Medicine Australia: Pharmaceutical arm of J&J in Australia, with overlapping portfolios in oncology, immunology, and rare disease. Competes for the same HCP relationships, hospital listings, and PBS reimbursement slots as Pfizer Australia.
  • Sanofi Australia: Australian subsidiary of Sanofi with portfolio overlap in vaccines, rare disease, and specialty care. Operates the same PBS, HCP, and pharmacy distribution model targeting the same Australian prescriber base.
  • Eli Lilly Australia: Australian subsidiary of Eli Lilly with growing focus on oncology, diabetes, and immunology. Operates a similar PBS, HCP, and hospital-focused commercial model targeting the same Australian prescriber base as Pfizer Australia.
  • AbbVie Australia: Australian subsidiary of AbbVie with strong overlap in immunology, oncology, and neuroscience. Competes directly with Pfizer for HCP relationships, hospital listings, and PBS positions in Australia.
  • MSD Australia (Merck): Australian subsidiary of Merck & Co. with a comparable portfolio in vaccines, oncology, and hospital specialty. Competes head-to-head with Pfizer for HCP attention, hospital listings, and PBS positions.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Pfizer Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pfizer Australia leadership team

Management profile

Number of profiles

Profiles1 record

Pfizer Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pfizer Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Australia

What does Pfizer Australia do?

Pfizer Australia manufactures and sells biopharmaceutical products including prescription medicines, vaccines, and therapeutics across therapeutic areas such as Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are distributed via pharmacies, hospitals, wholesalers, and healthcare providers, with pricing governed by Australia's Pharmaceutical Benefits Scheme (PBS). The company also runs clinical trials, medicines access programs, and healthcare-professional support services.

Is Pfizer Australia a public or private company?

Pfizer Australia is a private company. It is classified as corporate owned and is currently operating.

When was Pfizer Australia founded?

Pfizer Australia was founded in 1960. It employs 51 to 100 people.

Where is Pfizer Australia based?

Pfizer Australia is headquartered in Sydney, Australia, in the Oceania region.

How does Pfizer Australia make money?

One revenue line is on record: prescription Medicines and Vaccines.

Who are Pfizer Australia's main competitors?

Direct peers on record are Bayer Australia, Roche Australia, GSK Australia, Novartis Australia, AstraZeneca Australia, Johnson & Johnson Innovative Medicine Australia, Sanofi Australia, Eli Lilly Australia, AbbVie Australia and MSD Australia (Merck).

Does Pfizer Australia have an API?

No public API is recorded for Pfizer Australia.

What industry is Pfizer Australia in?

Pfizer Australia's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales